𝔖 Bobbio Scriptorium

✦ LIBER ✦

PHP84 Lung Cancer Treatment: A Paradigm Shift to Targeted Therapies in Clinical Trial Settings in Asia

✍ Scribed by Gupta, J.; Gupta, P.; Kaur, H.; Jindal, R.

Book ID: 122266023
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 53 KB
Volume: 15
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2012.08.128

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB